1. Home
  2. GKOS vs ACT Comparison

GKOS vs ACT Comparison

Compare GKOS & ACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.17

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Logo Enact Holdings Inc.

ACT

Enact Holdings Inc.

HOLD

Current Price

$41.96

Market Cap

5.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
ACT
Founded
1998
1981
Country
US
US
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.6B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
GKOS
ACT
Price
$116.17
$41.96
Analyst Decision
Strong Buy
Hold
Analyst Count
14
3
Target Price
$133.07
$42.67
AVG Volume (30 Days)
770.3K
294.6K
Earning Date
05-14-2026
05-05-2026
Dividend Yield
N/A
1.98%
EPS Growth
0.36
6.33
EPS
N/A
3.30
Revenue
$383,481,000.00
$1,201,774,000.00
Revenue This Year
$23.29
$4.14
Revenue Next Year
$27.74
$2.41
P/E Ratio
N/A
$12.82
Revenue Growth
21.85
4.17
52 Week Low
$73.16
$31.28
52 Week High
$142.50
$44.80

Technical Indicators

Market Signals
Indicator
GKOS
ACT
Relative Strength Index (RSI) 52.32 53.17
Support Level $103.55 $42.70
Resistance Level $121.70 $43.99
Average True Range (ATR) 5.70 1.23
MACD -0.23 -0.03
Stochastic Oscillator 63.83 51.07

Price Performance

Historical Comparison
GKOS
ACT

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About ACT Enact Holdings Inc.

Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.

Share on Social Networks: